16:28 , Jun 22, 2017 |  BC Innovations  |  Translation in Brief

Toxoplasmic indigestion

A team from the University of Michigan Medical School has discovered a new strategy and target for clearing out persistent reservoirs of the parasite Toxoplasma gondii . The approach involves disrupting lysosomal consumption of autophagosomes...
15:49 , Mar 28, 2017 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Other A click chemistry-based method for delivering prodrugs to tumor cells could help treat cancer with minimal toxicity. The method has two steps: IV injection of an acetylated azidomannosamine analog that is activated by...
07:00 , Aug 13, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Cathepsin B; cathepsin L (CTSL); α-synuclein (SNCA)

Neurology INDICATION: Parkinson's disease (PD) In vitro studies suggest activating cathepsin L and cathepsin B could help treat PD. In lysosomal extracts from mouse liver and brain cells, cathepsin L and cathepsin B cleaved SNCA...
07:00 , Apr 28, 2014 |  BC Week In Review  |  Clinical News

HTI-501: Additional Phase II data

Data from 36 evaluable women with moderate to severe edematous fibrosclerotic panniculopathy in the Phase II portion of a blinded, Mexican Phase I/II trial showed that subcutaneous HTI-501 met the primary endpoint of a greater...
07:00 , Apr 21, 2014 |  BC Week In Review  |  Clinical News

OxiGene preclinical data

In a mouse model of SCCHN, KGP94 significantly delayed tumor growth at doses of >=10 mg/kg vs. control mice. Data were presented at the American Association for Cancer Research meeting in San Diego. OxiGene could...
07:00 , Jul 15, 2013 |  BC Week In Review  |  Clinical News

HTI-501: Additional Phase I/II data

Interim data from 12 evaluable women with moderate to severe edematous fibrosclerotic panniculopathy in the Phase II portion of a blinded, Latin American Phase I/II trial showed that subcutaneous HTI-501 led to a median improvement...
08:00 , Feb 13, 2012 |  BC Week In Review  |  Clinical News

HTI-501: Interim Phase I/II data

Interim data from the open-label, dose-escalation Phase I portion of a blinded, placebo-controlled, Latin American Phase I/II trial in women with moderate to severe edematous fibrosclerotic panniculopathy showed that a single subcutaneous injection of HTI-501...
07:00 , Oct 10, 2011 |  BC Week In Review  |  Clinical News

HTI-501: Phase I/II started

Halozyme began a blinded, placebo-controlled, Latin American Phase I/II trial of HTI-501. The open-label, dose-escalation Phase I portion will evaluate single injections of HTI-501 in up to 48 patients and the Phase II portion will...
07:00 , Apr 25, 2011 |  BC Week In Review  |  Clinical News

OxiGene preclinical data

In vitro, KGP94 significantly inhibited cell invasion and migration of human prostate cancer cells vs. controls. KGP94 is small molecule cathepsin L inhibitor. Data were presented at the American Association for Cancer Research meeting in...
07:00 , Apr 25, 2011 |  BC Week In Review  |  Clinical News

OxiGene preclinical data

In a mouse model of breast cancer, once-daily KGP94 for 5 days significantly increased the mean time for tumors to reach a volume of 500 mm 3 vs. vehicle-treated controls (25.57 vs. 18.25 days, p<0.05)....